Table 1

Frequency of mutations and estimated risk of EOC in candidate genes (p<0.05) from targeted sequencing and exome sequencing

Set*HistotypeGeneControlsCasesOr (95% CI)P value
No.%No.%
TSOverallPOLK90.17290.523.04 (1.43 to 6.43)0.0037
PALB260.12190.343.10 (1.23 to 7.78)0.016
SLX440.08130.233.08 (1.00 to 9.48)0.0049
FBXO1090.1730.0530.30 (0.08 to 1.11)0.071
Non-carrier517499.5549298.8
HGSOCPOLK90.17270.533.17 (1.48 to 6.79)0.003
PALB260.12180.353.30 (1.30 to 8.38)0.012
SLX440.08130.253.51 (1.13 to 10.9)0.029
FBXO1090.1730.0590.32 (0.09 to 1.18)0.086
Non-carrier517499.5506298.8
ESOverallPOLK70.7760.720.94 (0.32 to 2.82)0.92
PALB220.2230.361.65 (0.28 to 9.93)0.58
SLX40020.24NA
FBXO1010.1100
Non-carrier90398.981898.7
HGSOCPOLK70.7760.720.94 (0.32 to 2.82)0.92
PALB220.2230.361.66 (0.28 to 9.94)0.58
SLX40020.24NA
FBXO1010.1100NA
Non-carrier90398.981798.7
  • *TS: targeted sequencing; ES: exome sequencing.

  • EOC, epithelial ovarian cancer; HGSOC, high-grade serous ovarian cancer; OCAC, Ovarian Cancer Association Consortium.